As early as 2016, the team of Nobel Prize winner Jennifer DouDNA published a paper in Nature and developed a miniaturized new CRISPR gene editing system - CasX. Since then, the Jennifer Doudna team further parsed how CasX gene editing works and founded a company called Scribe Therapeutics.
Jennifer Professor Doudna
Scribe Therapeutics is committed to developing a CasX-based genome editing and delivery tool - CasX-Editors, to achieve better gene editing tool attributes from three aspects - higher activity, stronger specificity, and easier delivery. Scribe completed a US$20 million Series A financing at the end of 2020 and a US$100 million Series B financing in March 2021.
September 27, 2022, pharmaceutical giant Sanofi (Sanofi ) announced a cooperation with Scribe Therapeutics, and Sanofi will cooperate with Scribe to develop NK cell therapies based on CRISPR gene editing to fight cancer. In this collaboration, Sanofi will pay a $25 million advance payment, Scribe will also receive a milestone payment of up to $1 billion, as well as a sales share of the cooperative development products and a royalty .
HSFrank Nestle, global research director and chief scientific officer of Sanofi, said the collaboration with Scribe complements Sanofi’s strong research efforts in the field of NK cell therapy and provides Sanofi scientists with unique CRISPR-based engineering technology to better enable a new generation of spot-on NK cell therapies.
Before this, Scribe Therapeutics had reached a partnership with pharmaceutical giant Biogen to develop treatments for ALS and another undisclosed disease.
Scribe's logo pays tribute to the famous "Photo No. 51"
Rosalind Franklin in May 1952, which directly inspired the birth of the structure of the double helix of DNA.
Scribe Therapeutics There are currently 5 research and development directions: neurological disease (Huntington's disease, familial ALS, spinal muscular atrophy, Parkinson's disease , early onset familial Alzheimer's disease, angel syndrome, etc.), ophthalmic disease (retinitis pigmentosa, cone-rod malnutrition, congenital melanosis, glaucoma , total color blindness, etc.), multi-system, muscle and metabolic diseases disease (cystic fibrosis, Duchenne muscular dystrophy, α1-antitrypsin deficiency, progestinosis, familial hypercholesterolemia , phenylketonuria, etc.), hematopoietic dysfunction disease (sickle cell disease, severe combined immunodeficiency, Fanconi anemia, hemophilia A/B, chronic granuloma, vasculophilia), cell therapy (CAR-T, NK, TiL, HSC, iPSC).
Scribe Therapeutics is committed to developing a CasX-based genome editing and delivery tool - CasX-Editors, achieving better gene editing tool attributes from three aspects - higher activity, stronger specificity, and easier delivery.
In addition, due to the fierce patent dispute between several companies of Jennifer Doudna team and the Zhang Feng team, CasX developed by Scribe Therapeutics avoids patent disputes.
Reference:
https://www.scribetx.com/press-release-scribe-therapeutics-announces-research-collaboration-with-sanofi-to-accelerate-breakthrough-crispr-based-cell-therapies-for-cancer/
